SPEAKERS

CEO, SHORTWAVE PHARMA

Rivki is a biotech entrepreneur with over 2 decades of financial and management experience specializing in strategy and business development in the US, Europe and Asia. She is an advisor to the Israeli government, incubator programs and investment funds.

FOUNDER, APEIRON INVESTMENT GROUP

Christian Angermayer is a serial entrepreneur and investor who builds and invests in companies that are shaping the Next Human Agenda: a future in which technology empowers people to live longer, healthier, and happier lives.

LABOUR, MEMBER OF UK PARLIAMENT

Charlotte has been the MP for Warrington North since December 2019, and was previously an officer for the GMB union. She is a member of the Business and Trade Committee, and is a campaigner around issues of mental health, including drawing on her own lived experience of PTSD.

PROFESSOR OF NEUROLOGY & PSYCHIATRY, DIRECTOR PSYCHEDELICS DIVISION, NEUROSCAPE, UCSF

Robin Carhart-Harris is a psychologist and neuroscientist and Head of the Centre for Psychedelic Research, Division of Brain Sciences, Faculty of Medicine at Imperial College London. He coordinated the first clinical study of psilocybin in the UK and the first clinical study of a classic psychedelic drug in the UK for over 40 years.

PROFESSOR OF PSYCHOPHARMACOLOGY, UNIVERSITY OF EXETER & AWAKN LIFE SCIENCES

Celia’s research has focused on both the therapeutic and adverse effects of a variety of psychoactive substances. Celia is currently investigating the unique subjective effects of psychedelics and psychedelic-like compounds with the aim of better understanding how to harness these effects to catalyse psychological therapies.

MEP, EUROPEAN PARLIAMENT

Mikuláš Peksa is a Czech biophysicist, political activist, and a member of the European Parliament. As an MEP he advocates for funding for psychedelic research.

HEALTH EDITOR, WOMEN'S HEALTH
Claudia Canavan is a health journalist and editor. Her work has covered the potential and problems inherent in psychedelic-assisted psychotherapy, the happiness benefits of less conventional relationships and the current issues in the U.K. medicinal cannabis system. Currently, she serves as health editor at Women’s Health magazine.

MEP FOR MALTA, EUROPEAN PARLIAMENT

Graduated in European Union Politics and Law, Cyrus Engerer became a Member of European Parliament in 2020 whereby he sits as a full member on the Committee for Environment, Public Health and Food Safety (ENVI) and on the Special Committee Beating Cancer.

CHIEF MEDICAL OFFICER, CYBIN INC

Amir Inamdar is the Chief Medical Officer of Cybin Inc. He is a qualified psychiatrist and pharmaceutical physician with over 20 years of clinical and drug development experience. Previously, he has led clinical drug discovery teams as a medical director for AstraZeneca, Takeda, and GlaxoSmithKline.

CHIEF COMMERCIAL OFFICER, CLERKENWELL HEALTH

Commercial barrister turned drug policy reform advocate. Co-founded Hanway Associates, a strategic advisory firm working in the nascent European cannabis sector. Previously worked at Beckley Foundation and Volteface.

ASSOCIATE PROFESSOR & HONORARY CONSULTANT PSYCHIATRIST, OXFORD UNIVERSITY

Rebecca Park is an expert in eating disorders whose clinical neuroscience research innovates novel treatments. She has over 20 years experience as a specialist in Eating Disorders Psychiatry, and translates deep clinical understanding with patients into novel treatment development. She currently leads the first UK trial of Deep Brain Stimulation for severe Anorexia Nervosa and also collaborates with David Nutt and team at Imperial in the study of Psilocybin for Anorexia Nervosa.

CHIEF MEDICAL OFFICER, COMPASS PATHWAYS PLC

Guy research interests have been focused on the treatment of mood disorder and, increasingly, the potential to improve treatment using new technology and new drugs, notably psychedelics. He was part of the team that developed COMPASS Pathways’ phase IIb clinical trial and acted initially as its coordinating principal investigator.

CLINICAL RESEARCHER, HONORARY CONSULTANT PSYCHIATRIST, OXFORD UNIVERSITY

Beata’s research focuses on the psychopharmacology of mood disorders - depression and bipolar disorder - and psychological mechanisms of antidepressant drug action. Working as part of Prof Philip Cowen's Clinical Psychopharmacology group, Beatra explores her cognitive neuropsychological model of drug action in depressed populations.

CLINICAL SENIOR LECTURER & CONSULTANT PSYCHIATRIST, IMPERIAL COLLEGE LONDON

David conducts psychopharmacological research, using brain-imaging techniques such as PET and MRI. He was trained in PET imaging at Columbia University in New York and later undertook a PhD at University Hospital Rigshospitalet in Copenhagen.

WRITER, BROADCASTER & GP

Farrah Jarral is a medical doctor, freelance writer and radio presenter with an interest in the clinical application of psilocybin for the treatment of depression and addiction disorders.

FEATURES WRITER, BENZINGA

Natan Ponieman is a writer, journalist and filmmaker covering psychedelic medicine, business, finance and macroeconomics as they intersect with culture, technology and social issues.

SENIOR DIRECTOR, FTI CONSULTING

Ariadna has 15 years of experience in investor relations, corporate communications and content creation. During her career, she has worked in Vancouver, Hong Kong and London, including six years in an IR role at a dual-listed company, a writer for The Economist and Head of Communications for Women in Mining UK.

FOUNDER AND EXECUTIVE DIRECTOR, PAREA

Tadeusz Hawrot is the founder of PAREA, the Psychedelic Access and Research European Alliance. He educates EU institutions on the potential of psychedelic healthcare.

FOUNDER & CEO, BEAUTIFUL SPACE

Sarah is a healthcare entrepreneur and sex and relationship therapist with 20 years working with plant medicine and altered states. She has 30 years experience working in education and program creation and is alumni to Cambridge University Institute for Sustainability Leadership

DEPUTY DIRECTOR, NEUROMEDICINES DISCOVERY CENTRE, MONASH UNIVERSITY

Chris Langmead is Professor, Deputy Director, and Better Medicines Theme Leader of the Neuromedicines Discovery Centre at the Monash Institute of Pharmaceutical Sciences (MIPS), a collaborative venture targeting new medicines development for poorly-treated mental health disorders.

JOURNALIST

Kate Spicer is a prominent lifestyle journalist who has documented the shifting attitudes in mainstream culture to drugs and drug use. She writes for several different newspapers, including The Sunday Times, FT HTSI and Daily Mail. She has also written books and made documentaries.

SECTION MANAGER, OREGON PSILOCYBIN SERVICES, OREGON HEALTH AUTHORITY

Angela Allbee joined the Oregon Health Authority Public Health Division as Oregon Psilocybin Services Section Manager after working to shape legislative policy for nearly a decade.

PSYCHEDELIC RESEARCH CLINICIAN, IMPERIAL COLLEGE LONDON

Christopher Timmermann (PhD) obtained a BSc in Psychology in Santiago, Chile and an MSc in Cognitive Neuroscience at the University of Bologna in Italy. He is currently a post-doc at Imperial College London at the Centre for Psychedelic Research, where he leads the DMT Research Group.

HEALTH REPORTER, BUSINESS INSIDER

Dr. Catherine Schuster-Bruce is Business Insider’s health reporter and a medical doctor. She covers how psychedelic drugs such as MDMA, psilocybin and LSD might be used in healthcare.

HEAD OF MRI APPLICATIONS, INVICRO LONDON

Matt Wall is a psychologist, neuroscientist and specialist in neuroimaging, particularly functional Magnetic Resonance Imaging of the human brain. He completed his PhD at Cambridge, post-doctoral positions at Royal Holloway and UCL, and is currently head of MRI applications at Invicro London, and an honorary Senior Lecture at Imperial College.

SENIOR CLINICAL TRIALS MANAGER, CLERKENWELL HEALTH

15 years of experience in the set-up and delivery of mental healthcare research with leadership roles in large research programmes at the National Institute for Health Research (NIHR) and University of Cambridge.

SENIOR REPORTER, SIFTED

Tim started his career on the Guardian's tech weekly podcast, before becoming a producer at BBC World Service Radio. He's been reporting from Spain since 2017, working for BBC, Deutsche Welle, Pink News and Radio New Zealand.

SENIOR CONSULTANT, FTI CONSULTING

Kim has experience working in, designing, and conducting academic and market research. She is responsible for the team’s psychological and behavioural research, including psychometric capabilities. During her time at FTI, she has worked on various qualitative and quantitative research projects with large-cap clients including Microsoft, HSBC, Ashurst LLP, Lloyds Bank Group, and Amazon.

CEO & CO-FOUNDER, ERAMOL

Peter has over 15 years’ experience in the pharmaceutical industry. Qualifying as a pharmacist in 2004, he worked at the Institute of Cancer Research on pharmacogenomic and drug discovery, before moving into commercial and clinical sterile and non-sterile production roles in the UK NHS and commercial organisations.

PSYCHOLOGY & PSYCHOTHERAPY LEAD IN PSYCHEDELICS, KINGS COLLEGE LONDON

With an interest in psychopharmacology and clinical expertise in treating psychological trauma at the IoPPN, Liam works as a clinical investigator, research therapist and therapist trainer on studies exploring the safety and efficacy of psychedelics.

PSYCHOLOGIST & PSYCHEDELIC RESEARCHER, IMPERIAL CENTRE FOR PSYCHEDELIC RESEARCH

Ashleigh is a psychologist in the Tavistock Complex Trauma Service, and a member of the Imperial Centre for Psychedelic Research. She is carrying out qualitative research into therapists' experiences of using psychedelic assisted therapy with patients, as well as investigating patients’ experiences of psilocybin treatment.

FOUNDING CEO & PRESIDENT, PHARMALA BIOTECH

With over a decade of experience as a Public Affairs and Regulatory expert, Nick Kadysh is the founder and CEO of PharmAla Biotech, a Toronto-based Life Sciences company focused on the manufacturing and development of MDMA and MDXX-class molecules.

CHIEF SCIENTIFIC OFFICER, TRANSPHARMATION LTD.

Guy brings over 25 years International CNS Research and Development experience with major BioPharma organizations such as Glaxo-Wellcome, Hoffmann-La Roche, Schering Plough and NPS Pharmaceuticals.

CO-FOUNDER & CO-DIRECTOR, PSYPAN

Ian Roullier is the co-founder of the Psychedelic Participant Advocacy Network (PsyPAN). Ian has suffered from depression and anxiety for most of his adult life and was a participant in both the Imperial College London psilocybin for depression pilot study (2015) and the COMPASS Pathways psilocybin trial (2019).

FOUNDER & EDITOR, PSYCHDELIC ALPHA

Josh Hardman is Founder and Editor of Psychedelic Alpha, a website, newsletter and boutique consultancy firm where he spends most of his time exploring the curious intersection of psychedelics and business.

EDITOR, PSYCHEDELIC HEALTH

Stephanie is the editor of Psychedelic Health, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, and in 2015, received her NCTJ diploma whilst working as a reporter in North Wales.

PSILOCYBIN RESCHEDULING PROJECT MANAGER, CDPRG

Timmy Davis is a trainee at the Site for Contemporary Psychoanalysis and the Psilocybin Rescheduling Project manager at the Conservative Drug Policy Reform Group. He is a contributing member of Drug Science's Medical Psychedelics Working Group and provides psychological support on the psilocybin for treatment resistant depression trials at Kings College London.

CO-INVESTIGATOR, SHEBA MEDICAL CENTER DEPARTMENT FOR EATING DISORDERS

Yoel is Co-Investigator at the center for eating disorders at Sheba medical center and has experience in working with adolescents and adults from a multitude of public and private organizations.

PSYCHEDELIC TRIAL PARTICIPANT, PSYPAN

Took part in the 2015 Imperial College Psilocybin trial for treatment resistant depression with hugely positive results. PsiDeR clinical trial steering group member. Working with PsyPan and Beckley Institute to develop best practices for psychedelic trials.

DIRECTOR, OEV PARTNERS

Chris is a passionate advocate for effective, evidence-based change who knows that sharing compelling stories and experiences will influence and improve culture, practice and policy.

CHAIRMAN, LEAP EUROPE

Neil is a former uk police officer and undercover drugs operative. Now he’s an active member of the international drug policy reform movement.

RESEARCH OFFICER, IMPERIAL COLLEGE LONDON

Rayyan is currently undertaking his Ph.D. at Imperial College after being awarded the Medical Research Council Doctoral Training 3.5 year fellowship (MRC DTP). As a member of the Centre for Psychedelic Research and Neuropsychopharmacology group, he is working to complete a series of multimodal neuroimaging investigations in addicted populations.

PHD CANDIDATE, IMPERIAL COLLEGE LONDON

Tommaso Barba is a PhD candidate at the Centre for Psychedelic Research, Imperial College London. Tommaso's research is focused on understanding the potential of psychedelic drugs for well-being and human flourishing and the brain effects of short-acting psychedelics, like 5-MeO-DMT.